Introduced
by
To impose a new mandate on manufacturers of prescription drugs, to file detailed reports with the state on the costs associated with developing and marketing prescription drugs whose wholesale cost is more than $40 for a course of treatment. The bill would also create a state prescription drug “work group” comprised of individuals representing specified interests to recommend policies to mitigate the expense incurred by state medical welfare programs in providing drugs to beneficiaries.
Referred to the Committee on Health Policy
